Name | Number of supported studies | Average coverage | |
---|---|---|---|
macrophage | 44 studies | 53% ± 21% | |
conventional dendritic cell | 29 studies | 69% ± 17% | |
dendritic cell | 28 studies | 56% ± 25% | |
classical monocyte | 26 studies | 72% ± 14% | |
monocyte | 24 studies | 58% ± 21% | |
non-classical monocyte | 23 studies | 85% ± 12% | |
B cell | 16 studies | 31% ± 9% | |
myeloid cell | 16 studies | 59% ± 20% | |
memory B cell | 14 studies | 24% ± 5% | |
naive B cell | 13 studies | 22% ± 5% | |
neutrophil | 12 studies | 51% ± 17% | |
microglial cell | 10 studies | 35% ± 17% | |
alveolar macrophage | 8 studies | 63% ± 21% | |
mononuclear phagocyte | 7 studies | 53% ± 19% | |
mast cell | 7 studies | 19% ± 6% | |
hematopoietic precursor cell | 6 studies | 40% ± 9% | |
leukocyte | 6 studies | 36% ± 15% | |
intermediate monocyte | 6 studies | 66% ± 27% | |
plasmacytoid dendritic cell | 5 studies | 27% ± 10% | |
hematopoietic stem cell | 5 studies | 23% ± 6% | |
precursor B cell | 5 studies | 37% ± 17% | |
monocyte-derived dendritic cell | 4 studies | 56% ± 30% | |
inflammatory macrophage | 4 studies | 42% ± 17% | |
Langerhans cell | 3 studies | 75% ± 10% | |
plasmablast | 3 studies | 43% ± 7% | |
common myeloid progenitor | 3 studies | 48% ± 11% | |
immature B cell | 3 studies | 38% ± 14% | |
pro-B cell | 3 studies | 32% ± 15% | |
tissue-resident macrophage | 3 studies | 53% ± 11% | |
germinal center B cell | 3 studies | 36% ± 5% | |
astrocyte | 3 studies | 25% ± 7% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 100% | 6318.87 | 578 / 578 | 96% | 54.92 | 1108 / 1155 |
breast | 94% | 1083.81 | 430 / 459 | 96% | 41.03 | 1070 / 1118 |
intestine | 88% | 980.48 | 850 / 966 | 82% | 29.61 | 433 / 527 |
bladder | 95% | 967.95 | 20 / 21 | 72% | 31.85 | 362 / 504 |
adrenal gland | 93% | 1161.52 | 240 / 258 | 60% | 13.90 | 139 / 230 |
thymus | 65% | 502.09 | 424 / 653 | 87% | 33.22 | 524 / 605 |
prostate | 78% | 625.67 | 190 / 245 | 74% | 13.94 | 369 / 502 |
skin | 60% | 408.37 | 1082 / 1809 | 91% | 55.04 | 429 / 472 |
esophagus | 65% | 493.73 | 939 / 1445 | 85% | 29.31 | 156 / 183 |
kidney | 55% | 510.34 | 49 / 89 | 93% | 46.72 | 835 / 901 |
brain | 45% | 384.06 | 1192 / 2642 | 97% | 58.32 | 686 / 705 |
stomach | 54% | 449.47 | 194 / 359 | 86% | 40.60 | 246 / 286 |
uterus | 54% | 361.05 | 92 / 170 | 85% | 32.67 | 391 / 459 |
ovary | 33% | 211.81 | 60 / 180 | 96% | 52.24 | 413 / 430 |
liver | 54% | 456.10 | 121 / 226 | 64% | 17.56 | 260 / 406 |
pancreas | 23% | 171.15 | 75 / 328 | 90% | 46.28 | 161 / 178 |
lymph node | 0% | 0 | 0 / 0 | 100% | 245.06 | 29 / 29 |
peripheral blood | 100% | 48110.28 | 929 / 929 | 0% | 0 | 0 / 0 |
spleen | 100% | 10395.21 | 241 / 241 | 0% | 0 | 0 / 0 |
adipose | 99% | 2000.37 | 1193 / 1204 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 93% | 53.71 | 42 / 45 |
blood vessel | 76% | 984.80 | 1008 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 69% | 17.48 | 55 / 80 |
heart | 56% | 425.32 | 478 / 861 | 0% | 0 | 0 / 0 |
muscle | 6% | 31.02 | 51 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0090402 | Biological process | oncogene-induced cell senescence |
GO_1905453 | Biological process | regulation of myeloid progenitor cell differentiation |
GO_0010629 | Biological process | negative regulation of gene expression |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0002572 | Biological process | pro-T cell differentiation |
GO_0036462 | Biological process | TRAIL-activated apoptotic signaling pathway |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0045579 | Biological process | positive regulation of B cell differentiation |
GO_1900745 | Biological process | positive regulation of p38MAPK cascade |
GO_0032088 | Biological process | negative regulation of NF-kappaB transcription factor activity |
GO_0120186 | Biological process | negative regulation of protein localization to chromatin |
GO_1901223 | Biological process | negative regulation of non-canonical NF-kappaB signal transduction |
GO_0070102 | Biological process | interleukin-6-mediated signaling pathway |
GO_1904178 | Biological process | negative regulation of adipose tissue development |
GO_0030154 | Biological process | cell differentiation |
GO_0045646 | Biological process | regulation of erythrocyte differentiation |
GO_1902895 | Biological process | positive regulation of miRNA transcription |
GO_0002573 | Biological process | myeloid leukocyte differentiation |
GO_1905036 | Biological process | positive regulation of antifungal innate immune response |
GO_0006355 | Biological process | regulation of DNA-templated transcription |
GO_0043314 | Biological process | negative regulation of neutrophil degranulation |
GO_0098508 | Biological process | endothelial to hematopoietic transition |
GO_0002357 | Biological process | defense response to tumor cell |
GO_0051090 | Biological process | regulation of DNA-binding transcription factor activity |
GO_1904238 | Biological process | pericyte cell differentiation |
GO_1904151 | Biological process | positive regulation of microglial cell mediated cytotoxicity |
GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
GO_0045815 | Biological process | transcription initiation-coupled chromatin remodeling |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0005654 | Cellular component | nucleoplasm |
GO_0000785 | Cellular component | chromatin |
GO_0005667 | Cellular component | transcription regulator complex |
GO_0005634 | Cellular component | nucleus |
GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
GO_0140297 | Molecular function | DNA-binding transcription factor binding |
GO_0000981 | Molecular function | DNA-binding transcription factor activity, RNA polymerase II-specific |
GO_0000987 | Molecular function | cis-regulatory region sequence-specific DNA binding |
GO_0043565 | Molecular function | sequence-specific DNA binding |
GO_0003682 | Molecular function | chromatin binding |
GO_0060090 | Molecular function | molecular adaptor activity |
GO_0000976 | Molecular function | transcription cis-regulatory region binding |
GO_0097677 | Molecular function | STAT family protein binding |
GO_0061629 | Molecular function | RNA polymerase II-specific DNA-binding transcription factor binding |
GO_0051525 | Molecular function | NFAT protein binding |
GO_0003700 | Molecular function | DNA-binding transcription factor activity |
GO_0003723 | Molecular function | RNA binding |
GO_0001216 | Molecular function | DNA-binding transcription activator activity |
GO_0140311 | Molecular function | protein sequestering activity |
GO_0001217 | Molecular function | DNA-binding transcription repressor activity |
GO_0005515 | Molecular function | protein binding |
GO_0042826 | Molecular function | histone deacetylase binding |
Gene name | SPI1 |
Protein name | Spi-1 proto-oncogene Transcription factor PU.1 (31 kDa-transforming protein) |
Synonyms | |
Description | FUNCTION: Pioneer transcription factor, which controls hematopoietic cell fate by decompacting stem cell heterochromatin and allowing other transcription factors to enter otherwise inaccessible genomic sites. Once in open chromatin, can directly control gene expression by binding genetic regulatory elements and can also more broadly influence transcription by recruiting transcription factors, such as interferon regulatory factors (IRFs), to otherwise inaccessible genomic regions . Transcriptionally activates genes important for myeloid and lymphoid lineages, such as CSF1R (By similarity). Transcriptional activation from certain promoters, possibly containing low affinity binding sites, is achieved cooperatively with other transcription factors. FCER1A transactivation is achieved in cooperation with GATA1 (By similarity). May be particularly important for the pro- to pre-B cell transition . Binds (via the ETS domain) onto the purine-rich DNA core sequence 5'-GAGGAA-3', also known as the PU-box . In vitro can bind RNA and interfere with pre-mRNA splicing (By similarity). . |
Accessions | ENST00000533030.1 ENST00000227163.8 [P17947-2] P17947 F5H3K6 ENST00000533968.1 ENST00000378538.8 [P17947-1] F5GZ94 |